BACKGROUND: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgitation (CVR) in persons with Parkinson's disease. It is unclear whether the CVR risk is increased with ergot-dopamine agonist use in persons with hyperprolactinaemia, in whom the dose is much lower. OBJECTIVE: The aim of the study was to explore the association between different dopamine agonists and CVR in patients with Parkinson's disease or hyperprolactinaemia. DESIGN: Nested case-control studies conducted separately in cohorts of Parkinson's disease and hyperprolactinaemia patients. Cases were patients who developed newly diagnosed CVR. Controls were CVR-free patients from the same cohorts and were matched to cases by age, sex, database and calendar year. SETTING AND PATIENTS: Study patients were identified from over 4.5 million persons in The Health Improvement Network (THIN; UK), Health Search (Italy), and Integrated Primary Care Information (IPCI; the Netherlands) general practice databases in the years 1996-2007. The Parkinson's disease cohort included new users of dopamine agonists or levodopa, while the hyperprolactinaemia cohort included new users or non-users of dopamine agonists. MAIN OUTCOME MEASURE: Risk of newly diagnosed CVR with dopamine agonist use compared with levodopa use in the Parkinson's disease cohort, and dopamine agonist-naïve patients in the hyperprolactinaemia cohort. RESULTS: In the Parkinson's disease cohort (7893 dopamine agonist users, 11 766 levodopa users), 85 incident CVR cases were identified. Increased CVR risk was observed for ergot dopamine agonists (adjusted OR [OR(adj)] 3.82; 95% CI 2.14, 6.81), but not for non-ergot dopamine agonists (OR(adj) 1.20; 95% CI 0.63, 2.29). In the hyperprolactinaemia cohort (6740 dopamine agonist users and 14 299 dopamine agonist-naïve patients), 37 CVR cases were identified during a mean follow-up of 4.5 years and 3.5 years for new users and non-users of dopamine agonists, respectively. However, no association with ever use of ergot dopamine agonists was observed (OR(adj) 0.47; 95% CI 0.20, 1.19). CONCLUSION: Ergot-derived dopamine agonists are associated with an increased risk of CVR in Parkinson's disease but not in hyperprolactinaemia patients.
BACKGROUND: There is growing evidence that ergot dopamine agonists may induce cardiac valve regurgitation (CVR) in persons with Parkinson's disease. It is unclear whether the CVR risk is increased with ergot-dopamine agonist use in persons with hyperprolactinaemia, in whom the dose is much lower. OBJECTIVE: The aim of the study was to explore the association between different dopamine agonists and CVR in patients with Parkinson's disease or hyperprolactinaemia. DESIGN: Nested case-control studies conducted separately in cohorts of Parkinson's disease and hyperprolactinaemiapatients. Cases were patients who developed newly diagnosed CVR. Controls were CVR-free patients from the same cohorts and were matched to cases by age, sex, database and calendar year. SETTING AND PATIENTS: Study patients were identified from over 4.5 million persons in The Health Improvement Network (THIN; UK), Health Search (Italy), and Integrated Primary Care Information (IPCI; the Netherlands) general practice databases in the years 1996-2007. The Parkinson's disease cohort included new users of dopamine agonists or levodopa, while the hyperprolactinaemia cohort included new users or non-users of dopamine agonists. MAIN OUTCOME MEASURE: Risk of newly diagnosed CVR with dopamine agonist use compared with levodopa use in the Parkinson's disease cohort, and dopamine agonist-naïve patients in the hyperprolactinaemia cohort. RESULTS: In the Parkinson's disease cohort (7893 dopamine agonist users, 11 766 levodopa users), 85 incident CVR cases were identified. Increased CVR risk was observed for ergot dopamine agonists (adjusted OR [OR(adj)] 3.82; 95% CI 2.14, 6.81), but not for non-ergot dopamine agonists (OR(adj) 1.20; 95% CI 0.63, 2.29). In the hyperprolactinaemia cohort (6740 dopamine agonist users and 14 299 dopamine agonist-naïve patients), 37 CVR cases were identified during a mean follow-up of 4.5 years and 3.5 years for new users and non-users of dopamine agonists, respectively. However, no association with ever use of ergot dopamine agonists was observed (OR(adj) 0.47; 95% CI 0.20, 1.19). CONCLUSION: Ergot-derived dopamine agonists are associated with an increased risk of CVR in Parkinson's disease but not in hyperprolactinaemiapatients.
Authors: Guy Van Camp; Anja Flamez; Bernard Cosyns; Caroline Weytjens; Luc Muyldermans; Michel Van Zandijcke; Johan De Sutter; Patrick Santens; Pierre Decoodt; Christian Moerman; Danny Schoors Journal: Lancet Date: 2004-04-10 Impact factor: 79.321
Authors: James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2007-04 Impact factor: 2.890
Authors: J van der Lei; J S Duisterhout; H P Westerhof; E van der Does; P V Cromme; W M Boon; J H van Bemmel Journal: Ann Intern Med Date: 1993-11-15 Impact factor: 25.391
Authors: Judit Horvath; Robin D Fross; Galit Kleiner-Fisman; René Lerch; Hans Stalder; Suzanne Liaudat; William J Raskoff; Keith D Flachsbart; Harry Rakowski; Jean-Claude Pache; Pierre R Burkhard; Anthony E Lang Journal: Mov Disord Date: 2004-06 Impact factor: 10.338
Authors: Lisa B Nachtigall; Elena Valassi; Janet Lo; David McCarty; Jonathan Passeri; Beverly M K Biller; Karen K Miller; Andrea Utz; Steven Grinspoon; Elizabeth A Lawson; Anne Klibanski Journal: Clin Endocrinol (Oxf) Date: 2009-04-17 Impact factor: 3.478
Authors: F Bogazzi; S Buralli; L Manetti; V Raffaelli; T Cigni; M Lombardi; F Boresi; S Taddei; A Salvetti; E Martino Journal: Int J Clin Pract Date: 2008-05-06 Impact factor: 2.503
Authors: Jacqueline H Fortier; Beatrice Pizzarotti; Richard E Shaw; Robert J Levy; Giovanni Ferrari; Juan Grau Journal: Heart Date: 2019-05-25 Impact factor: 5.994
Authors: Janet Sultana; Ingrid Leal; Marcel de Wilde; Maria de Ridder; Johan van der Lei; Miriam Sturkenboom; Gianluca Trifiro' Journal: Drug Saf Date: 2019-06 Impact factor: 5.606